Alliancebernstein L.P. Buys Shares of 321,697 Allakos Inc (ALLK)

Alliancebernstein L.P. bought a new stake in shares of Allakos Inc (NASDAQ:ALLK) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 321,697 shares of the company’s stock, valued at approximately $14,473,000.

A number of other hedge funds have also added to or reduced their stakes in the stock. Strs Ohio purchased a new stake in shares of Allakos in the 3rd quarter valued at approximately $107,000. Rhumbline Advisers purchased a new stake in shares of Allakos in the 3rd quarter valued at approximately $285,000. Penserra Capital Management LLC purchased a new stake in shares of Allakos in the 3rd quarter valued at approximately $509,000. Wells Fargo & Company MN purchased a new stake in shares of Allakos in the 3rd quarter valued at approximately $623,000. Finally, Victory Capital Management Inc. purchased a new stake in shares of Allakos in the 3rd quarter valued at approximately $1,360,000. 37.78% of the stock is owned by institutional investors and hedge funds.

Several brokerages recently commented on ALLK. Zacks Investment Research downgraded shares of Allakos from a “hold” rating to a “sell” rating in a research report on Wednesday. William Blair began coverage on shares of Allakos in a research report on Monday, August 13th. They issued an “outperform” rating for the company. Goldman Sachs Group began coverage on shares of Allakos in a research report on Monday, August 13th. They issued a “neutral” rating and a $31.00 price target for the company. Finally, Jefferies Financial Group began coverage on shares of Allakos in a research report on Monday, August 13th. They issued a “buy” rating and a $53.00 price target for the company.

Shares of NASDAQ:ALLK opened at $60.76 on Friday. Allakos Inc has a 52 week low of $26.00 and a 52 week high of $62.32.

Allakos (NASDAQ:ALLK) last released its quarterly earnings data on Thursday, November 8th. The company reported ($0.34) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by ($0.10). On average, sell-side analysts forecast that Allakos Inc will post -1.23 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Alliancebernstein L.P. Buys Shares of 321,697 Allakos Inc (ALLK)” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another website, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2018/12/07/alliancebernstein-l-p-buys-shares-of-321697-allakos-inc-allk.html.

Allakos Profile

Allakos Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis.

Recommended Story: Dividend Stocks – Are They Right For You?

Want to see what other hedge funds are holding ALLK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allakos Inc (NASDAQ:ALLK).

Institutional Ownership by Quarter for Allakos (NASDAQ:ALLK)

Receive News & Ratings for Allakos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allakos and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply